MX2017014191A - Metodos de tratamiento de una enfermedad neurodegenerativa. - Google Patents
Metodos de tratamiento de una enfermedad neurodegenerativa.Info
- Publication number
- MX2017014191A MX2017014191A MX2017014191A MX2017014191A MX2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative disease
- treating
- methods
- phenylsulfonyl
- piperazinyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
La presente solicitud se refiere a nuevos usos de antagonistas del receptor 5-HT6, específicamente dosis altas de 3-fenilsulfonil-8-piperazinil-lil-quinolina, y a la combinación de antagonistas del receptor 5-HT6, específicamente 3-fenilsulfonil-8-piperazinil-lil-quinolina, con un inhibidor de acetilcolinesterasa para el tratamiento de una enfermedad neurodegenerativa.
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562158422P | 2015-05-07 | 2015-05-07 | |
US201562162068P | 2015-05-15 | 2015-05-15 | |
US201562162138P | 2015-05-15 | 2015-05-15 | |
US201562162060P | 2015-05-15 | 2015-05-15 | |
US201562162193P | 2015-05-15 | 2015-05-15 | |
US201562165034P | 2015-05-21 | 2015-05-21 | |
US201562168246P | 2015-05-29 | 2015-05-29 | |
US201562167986P | 2015-05-29 | 2015-05-29 | |
US201562169414P | 2015-06-01 | 2015-06-01 | |
US201562182225P | 2015-06-19 | 2015-06-19 | |
US201562189089P | 2015-07-06 | 2015-07-06 | |
US201562191189P | 2015-07-10 | 2015-07-10 | |
US201562201494P | 2015-08-05 | 2015-08-05 | |
US201562201513P | 2015-08-05 | 2015-08-05 | |
US201562239530P | 2015-10-09 | 2015-10-09 | |
US201562251534P | 2015-11-05 | 2015-11-05 | |
US201562256349P | 2015-11-17 | 2015-11-17 | |
US201562261115P | 2015-11-30 | 2015-11-30 | |
US201662289162P | 2016-01-29 | 2016-01-29 | |
US201662289643P | 2016-02-01 | 2016-02-01 | |
PCT/US2016/031359 WO2016179566A1 (en) | 2015-05-07 | 2016-05-06 | Methods of treating a neurodegenerative disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014191A true MX2017014191A (es) | 2018-08-01 |
Family
ID=57217933
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014191A MX2017014191A (es) | 2015-05-07 | 2016-05-06 | Metodos de tratamiento de una enfermedad neurodegenerativa. |
MX2017014192A MX2017014192A (es) | 2015-05-07 | 2016-05-06 | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014192A MX2017014192A (es) | 2015-05-07 | 2016-05-06 | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160324852A1 (es) |
EP (2) | EP3291816A4 (es) |
JP (2) | JP2018515607A (es) |
KR (2) | KR20180021693A (es) |
CN (2) | CN107847499A (es) |
AU (2) | AU2016256923A1 (es) |
CA (2) | CA2985370A1 (es) |
HK (1) | HK1245078A1 (es) |
IL (2) | IL255421A0 (es) |
MX (2) | MX2017014191A (es) |
NO (2) | NO20171934A1 (es) |
WO (2) | WO2016179566A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA009732B1 (ru) | 2003-07-22 | 2008-02-28 | Арена Фармасьютикалз, Инк. | Диарильные и арилгетероарильные производные мочевины в качестве модуляторов 5-ht-рецептора серотонина, пригодные для профилактики и лечения связанных с ним заболеваний |
EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
CA2989343A1 (en) | 2015-06-12 | 2016-12-15 | Yandong Wen | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US20210346374A1 (en) * | 2016-10-03 | 2021-11-11 | Suven Life Sciences Limited | Pharmaceutical compositions of 5-ht6 receptor antagonist |
MX2019005594A (es) * | 2016-11-15 | 2019-07-04 | H Lundbeck As | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. |
WO2018102824A1 (en) * | 2016-12-02 | 2018-06-07 | Axovant Sciences Gmbh | Methods for treating neurodegenerative disease |
PL3630098T3 (pl) * | 2017-05-24 | 2021-09-06 | H. Lundbeck A/S | Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4 |
JP7293129B2 (ja) | 2017-06-01 | 2023-06-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pde9阻害剤を含む医薬組成物 |
EP3628315A1 (en) * | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
EP3906927B1 (en) * | 2020-05-04 | 2022-05-25 | BIOPROJET Pharma | Use of dopamine d3 partial agonists for treating central nervous system disorders |
CN112587534A (zh) * | 2020-12-23 | 2021-04-02 | 佑嘉(杭州)生物医药科技有限公司 | 阿伦酸在制备治疗肝纤维化药物中的用途 |
WO2023128900A1 (en) * | 2021-12-30 | 2023-07-06 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising pimavanserin as active ingredient and relevant excipients |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60321558D1 (de) * | 2002-03-27 | 2008-07-24 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
ATE481096T1 (de) * | 2005-04-06 | 2010-10-15 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
EP2040755B1 (en) * | 2006-06-23 | 2011-05-18 | Laboratorios Del. Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
EP2254564A1 (en) * | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
CN102264354B (zh) * | 2008-10-28 | 2015-03-25 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
US20110251239A1 (en) * | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2016
- 2016-05-06 CA CA2985370A patent/CA2985370A1/en not_active Abandoned
- 2016-05-06 EP EP16790213.9A patent/EP3291816A4/en not_active Withdrawn
- 2016-05-06 KR KR1020177035167A patent/KR20180021693A/ko unknown
- 2016-05-06 AU AU2016256923A patent/AU2016256923A1/en not_active Abandoned
- 2016-05-06 US US15/149,053 patent/US20160324852A1/en not_active Abandoned
- 2016-05-06 WO PCT/US2016/031359 patent/WO2016179566A1/en active Application Filing
- 2016-05-06 KR KR1020177035169A patent/KR20180022661A/ko unknown
- 2016-05-06 MX MX2017014191A patent/MX2017014191A/es unknown
- 2016-05-06 WO PCT/US2016/031367 patent/WO2016179569A1/en active Application Filing
- 2016-05-06 CN CN201680036847.2A patent/CN107847499A/zh active Pending
- 2016-05-06 JP JP2018510697A patent/JP2018515607A/ja active Pending
- 2016-05-06 CN CN201680036907.0A patent/CN107949386A/zh active Pending
- 2016-05-06 AU AU2016258198A patent/AU2016258198A1/en not_active Abandoned
- 2016-05-06 EP EP16790210.5A patent/EP3291815A4/en not_active Withdrawn
- 2016-05-06 CA CA2985366A patent/CA2985366A1/en not_active Abandoned
- 2016-05-06 JP JP2018510696A patent/JP2018519358A/ja active Pending
- 2016-05-06 MX MX2017014192A patent/MX2017014192A/es unknown
-
2017
- 2017-11-05 IL IL255421A patent/IL255421A0/en unknown
- 2017-11-05 IL IL255423A patent/IL255423A0/en unknown
- 2017-12-05 NO NO20171934A patent/NO20171934A1/en not_active Application Discontinuation
- 2017-12-05 NO NO20171941A patent/NO20171941A1/en not_active Application Discontinuation
-
2018
- 2018-03-28 HK HK18104298.1A patent/HK1245078A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016256923A1 (en) | 2017-11-23 |
EP3291815A4 (en) | 2019-01-16 |
WO2016179566A1 (en) | 2016-11-10 |
WO2016179569A1 (en) | 2016-11-10 |
EP3291815A1 (en) | 2018-03-14 |
CN107949386A (zh) | 2018-04-20 |
AU2016258198A1 (en) | 2017-11-23 |
EP3291816A4 (en) | 2019-01-02 |
CA2985366A1 (en) | 2016-11-10 |
NO20171941A1 (en) | 2017-12-05 |
JP2018515607A (ja) | 2018-06-14 |
CA2985370A1 (en) | 2016-11-10 |
HK1245078A1 (zh) | 2018-08-24 |
IL255423A0 (en) | 2017-12-31 |
NO20171934A1 (en) | 2017-12-05 |
EP3291816A1 (en) | 2018-03-14 |
JP2018519358A (ja) | 2018-07-19 |
IL255421A0 (en) | 2017-12-31 |
MX2017014192A (es) | 2018-08-01 |
KR20180022661A (ko) | 2018-03-06 |
US20160324852A1 (en) | 2016-11-10 |
CN107847499A (zh) | 2018-03-27 |
KR20180021693A (ko) | 2018-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
TW201713333A (en) | Methods of treating a neurodegenerative disease | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
MX2017001490A (es) | Combinaciones de farmacos para tratar mieloma multiple. | |
MX2021007899A (es) | Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6. | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
NZ722600A (en) | Methods of treating mild brain injury | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades,. | |
TW201613610A (en) | Use of ginsenoside M1 for treating lupus nephritis | |
PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
IN2014CH00304A (es) | ||
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
IN2014CH01391A (es) | ||
NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
PH12016500824A1 (en) | Compositions and methods for the treatment of viral diseases with pde4 modulators | |
AR104570A1 (es) | Métodos de tratamiento de una enfermedad neurodegenerativa |